Endogenous and recombinant type I interferons and disease activity in multiple sclerosis

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Sellebjerg, Finn ^a   Krakauer, Martin ^a   Limborg, Signe ^a   Hesse, Dan ^a   Lund, Henrik ^b   Langkilde, Annika ^c   Søndergaard, Helle Bach ^a   Sørensen, Per Soelberg ^a  

^a University of Copenhagen   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; BETA1A INTERFERON; CD71 ANTIGEN; HLA DR ANTIGEN; INTERFERON; INTERFERON BETA SERINE; RECOMBINANT BETA INTERFERON; ALPHA4 INTEGRIN; BETA INTERFERON; LEUKOCYTE ANTIGEN; RECOMBINANT PROTEIN; TRANSFERRIN RECEPTOR;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; DENMARK; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST;

ADULT; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DENMARK; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; IMMUNOTHERAPY; INTEGRIN ALPHA4; INTERFERON TYPE I; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS; RECEPTORS, TRANSFERRIN; RECOMBINANT PROTEINS; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTE SUBSETS;

EID: 84862006018     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035927     Document Type: Article

References (38)

1. Stetson DB, Medzhitov R, (2006) Type I interferons in host defense. Immunity 25: 373-81.
2. Dhib-Jalbut S, Marks S, (2010) Interferon-beta mechanisms of action in multiple sclerosis. Neurology 74 (Suppl 1): S17-S24.
3. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39: 285-94.
4. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498-504.
5. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655-61.
6. van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, Baggen JM, Rustenburg F, et al. (2006) A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 7: 522-31.
7. Yamaguchi KD, Ruderman DL, Croze E, Wagner TC, Velichko S, et al. (2008) IFN-beta-regulated genes show abnormal expression in therapy-naive relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol 195: 116-20.
8. Hesse D, Krakauer M, Lund H, Søndergaard HB, Langkilde A, et al. (2010) Breakthrough disease during interferon-beta therapy in MS: No signs of impaired biologic response. Neurology 74: 1455-62.
9. Hesse D, Krakauer M, Lund H, Søndergaard HB, Limborg SJ, et al. (2011) Disease protection and interleukin-10 induction by endogenous interferon-beta in multiple sclerosis? Eur J Neurol 18: 266-72.
10. van der Voort LF, Vennegoor A, Visser A, Knol DL, Uitdehaag BM, et al. (2010) Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology 75: 1228-33.
11. Comabella M, Lunemann JD, Rio J, Sánchez A, López C, et al. (2009) A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 132: 3353-65.
12. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA, (2001) CD4+CD25high regulatory cells in human peripheral blood. J Immunol 167: 1245-53.
13. Michel L, Berthelot L, Pettre S, Wiertlewski S, Lefrère F, et al. (2008) Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J Clin Invest 118: 3411-9.
14. Jensen J, Langkilde AR, Fenst C, Nicolaisen MS, Roed HG, et al. (2004) CD4 T cell activation and disease activity at onset of multiple sclerosis. J Neuroimmunol 149: 202-9.
15. Krakauer M, Sorensen PS, Sellebjerg F, (2006) CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. J Neuroimmunol 181: 157-64.
16. Hafler DA, Fox DA, Manning ME, Schlossman SF, Reinherz EL, Weiner HL, (1985) In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med 312: 1405-11.
17. Khoury SJ, Guttmann CR, Orav EJ, Kikinis R, Jolesz FA, Weiner HL, (2000) Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol 57: 1183-9.
18. Sellebjerg F, Krakauer M, Hesse D, Ryder LP, Alsing I, et al. (2009) Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol 16: 1291-8.
19. Weinstock-Guttman B, Bhasi K, Badgett D, Tamaño-Blanco M, Minhas M, et al. (2008) Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol 205: 113-25.
20. Jensen J, Krakauer M, Sellebjerg F, (2005) Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b. Cytokine 29: 24-30.
21. Jensen J, Langkilde AR, Frederiksen JL, Sellebjerg F, (2006) CD8+ T cell activation correlates with disease activity in clinically isolated syndromes and is regulated by interferon-beta treatment. J Neuroimmunol 179: 163-72.
22. Sellebjerg F, Ross C, Koch-Henriksen N, Sørensen PS, Frederiksen JL, et al. (2005) CD26+ CD4+ T cell counts and attack risk in interferon-treated multiple sclerosis. Mult Scler 11: 641-5.
23. Barrau MA, Montalban X, Saez-Torres I, Brieva L, Barbera N, et al. (2000) CD4(+)CD45RO(+)CD49d(high) cells are involved in the pathogenesis of relapsing-remitting multiple sclerosis. J Neuroimmunol 111: 215-23.
24. Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF, (1997) VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 49: 1111-6.
25. Ossege LM, Sindern E, Patzold T, Malin JP, (2001) Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis. Int Immunopharmacol 1: 1085-100.
26. Tough DF, Borrow P, Sprent J, (1996) Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272: 1947-50.
27. Havenar-Daughton C, Kolumam GA, Murali-Krishna K, (2006) Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol 176: 3315-9.
28. Krug A, Veeraswamy R, Pekosz A, Kanagawa O, Unanue ER, et al. (2003) Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells. J Exp Med 197: 899-906.
29. Lombardi G, Dunne PJ, Scheel-Toellner D, Sanyal T, Pilling D, et al. (2000) Type 1 IFN maintains the survival of anergic CD4+ T cells. J Immunol 165: 3782-9.
30. Marrack P, Kappler J, Mitchell T, (1999) Type I interferons keep activated T cells alive. J Exp Med 189: 521-30.
31. Weinberg AD, Montler R, (2005) Modulation of TNF receptor family members to inhibit autoimmune disease. Curr Drug Targets Inflamm Allergy 4: 195-203.
32. Wiesemann E, Deb M, Trebst C, Hemmer B, Stangel M, Windhagen A, (2008) Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis. Mult Scler 14: 166-76.
33. Sellebjerg F, Datta P, Larsen J, Rieneck K, Alsing I, et al. (2008) Gene expression analysis of interferon-beta treatment in multiple sclerosis. Mult Scler 14: 615-21.
34. Weinstock-Guttman B, Badgett D, Patrick K, Hartrich L, Santos R, et al. (2003) Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 171: 2694-702.
35. Buttmann M, Merzyn C, Hofstetter HH, Rieckmann P, (2007) TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. J Neuroimmunol 190: 170-6.
36. Krakauer M, Sorensen PS, Khademi M, Olsson T, Sellebjerg F, (2006) Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. Scand J Immunol 64: 155-63.
37. Ravnborg M, Sorensen PS, Andersson M, Celius EG, Jongen PJ, et al. (2010) Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol 9: 672-80.
38. Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, et al. (2009) NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 8: 519-29.